Antiemetics and gastrointestinal drugs
The pathways that produce nausea and vomiting and the receptor each antiemetic blocks; dopamine antagonists and their extrapyramidal effects; 5-HT3, H1, muscarinic and NK1 antagonists; acid suppression with proton pump inhibitors and H2 antagonists; drugs for variceal bleeding; and laxatives, antidiarrhoeals and prokinetics.
By the end of this page you should be able to
- Describe the inputs to the vomiting centre and the receptors involved in each.
- Classify antiemetics by receptor and match each class to the cause of vomiting it suits.
- Explain the mechanism and treatment of drug-induced acute dystonia.
- Describe the pharmacology of proton pump inhibitors and their role in upper gastrointestinal bleeding.
- Describe the mechanisms of laxatives, loperamide, octreotide, terlipressin and erythromycin as a prokinetic.
Why we vomit
Vomiting is coordinated by a network in the medulla (around the nucleus tractus solitarius and a central pattern generator). It receives four main inputs, and each uses different receptors, which is the key to choosing a drug:
- Chemoreceptor trigger zone in the area postrema, outside the blood-brain barrier, so it samples blood: drugs (opioids, chemotherapy, digoxin), toxins, uraemia. Receptors: D2, 5-HT3, NK1 and opioid.
- Gut vagal afferents: irritation, distension, and serotonin released from enterochromaffin cells after chemotherapy or gastroenteritis. Receptor: 5-HT3.
- Vestibular system: motion sickness, vestibular neuritis. Receptors: H1 and muscarinic (M1).
- Cortex and limbic system: pain, smell, anticipation, anxiety; and raised intracranial pressure acting directly.
Antiemetics by receptor
- 5-HT3 antagonists (ondansetron, granisetron): block vagal afferents and the trigger zone; best for chemotherapy, postoperative and gastroenteritis-related vomiting; little effect on motion sickness. Adverse: headache, constipation, QT prolongation. Little sedation and no extrapyramidal effects.
- D2 antagonists: metoclopramide (also a prokinetic through 5-HT4 agonism and gut D2 block; avoid in bowel obstruction), prochlorperazine (a phenothiazine, also antihistaminic and anticholinergic), droperidol and haloperidol (butyrophenones; sedating; useful in cannabinoid hyperemesis and in agitation), and domperidone (does not cross the blood-brain barrier, so few central effects; QT prolongation).
- Extrapyramidal effects of central D2 block: acute dystonia (oculogyric crisis, torticollis, trismus; most common in young people, especially young women, within hours to days), akathisia (restlessness, often mistaken for anxiety), and with long use parkinsonism and tardive dyskinesia. Dystonia reflects a relative excess of cholinergic activity in the striatum when dopamine is blocked, so it is reversed by a centrally acting anticholinergic (benztropine) or an antihistamine with anticholinergic action. D2 antagonists worsen Parkinson disease and can precipitate neuroleptic malignant syndrome.
- H1 antihistamines (promethazine, cyclizine) and antimuscarinics (hyoscine hydrobromide): vestibular causes and motion sickness. Sedation and anticholinergic effects; hyoscine patches cause blurred vision and confusion in older people.
- NK1 antagonists (aprepitant): block substance P; used for chemotherapy-induced vomiting; CYP3A4 interactions.
- Dexamethasone: adds to other antiemetics in chemotherapy and postoperative nausea; mechanism uncertain.
- Combining drugs from different classes works better than escalating one.
Acid suppression
Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) are inactive prodrugs and weak bases. They concentrate in the acidic canaliculi of parietal cells, where acid converts them to a reactive sulfenamide that covalently and irreversibly binds the H+/K+ ATPase. Acid secretion recovers only as new pumps are made, so the effect outlasts the short plasma half-life, and the drugs work best when pumps are active (before a meal). Metabolised by CYP2C19 (genetic variation; omeprazole and esomeprazole reduce the activation of clopidogrel). Long-term adverse effects: hypomagnesaemia, C. difficile and enteric infections, acute interstitial nephritis, B12 deficiency, fractures.
In upper GI bleeding from peptic ulcer, a high intragastric pH helps a clot form and survive, because pepsin is inactive and platelet aggregation and clot stability are better near neutral pH. PPIs reduce rebleeding after endoscopic therapy.
H2 antagonists (famotidine) competitively block histamine on parietal cells; less complete suppression and tolerance develops. Antacids neutralise acid; sucralfate forms a protective layer over ulcer bases.
Bleeding, motility and bowel habit
- Variceal bleeding: terlipressin (a vasopressin analogue prodrug acting on V1 receptors) and octreotide (somatostatin analogue) constrict the splanchnic circulation and lower portal pressure. Terlipressin can cause ischaemia (cardiac, gut, digital) and hyponatraemia.
- Erythromycin is a motilin receptor agonist; given before endoscopy for upper GI bleeding it empties the stomach of blood and improves the view.
- Laxatives: osmotic (macrogol, lactulose; lactulose is also fermented to acids in the colon, trapping ammonia as ammonium, which is why it treats hepatic encephalopathy), stimulant (senna, bisacodyl: increase motility and secretion), bulk-forming (psyllium: needs fluid; can worsen opioid constipation), and softeners (docusate). Peripherally acting mu antagonists (methylnaltrexone, naloxegol) reverse opioid constipation without reversing analgesia because they do not cross the blood-brain barrier.
- Loperamide: a mu opioid agonist kept out of the brain by P-glycoprotein efflux; slows transit. Massive misuse, often with P-glycoprotein inhibitors, causes cardiotoxicity from cardiac sodium and potassium channel block (wide QRS, long QT, torsades).
- Hyoscine butylbromide: a quaternary antimuscarinic antispasmodic; no central effects.
Making the answer flow
- Start with the four inputs to the vomiting centre and their receptors; then each antiemetic answers itself.
- For a drug, give receptor, effect, uses, adverse effects explained from the receptor, and interactions.
- For PPIs, explain the prodrug activation; it accounts for timing, irreversibility and duration.
Where marks are lost
- Using ondansetron for motion sickness, or metoclopramide in bowel obstruction.
- Mistaking akathisia for anxiety and giving more of the drug.
- Treating acute dystonia with more dopamine antagonist rather than an anticholinergic.
- Saying PPIs act on histamine receptors, or that their effect ends with the plasma half-life.
- Forgetting that loperamide in large amounts is cardiotoxic.
Where this meets anaesthesia
- Postoperative nausea risk rises with female sex, non-smoking, previous postoperative nausea and postoperative opioids; combining antiemetics with different mechanisms works better than one.
- Ondansetron prolongs the QT interval; droperidol and other dopamine antagonists do too.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe the physiology of vomiting and how it guides antiemetic choice.
Show answer
- Medullary vomiting network with inputs from the chemoreceptor trigger zone, gut vagal afferents, vestibular system and higher centres.
- CTZ: D2, 5-HT3, NK1; gut: 5-HT3; vestibular: H1, M1; cortex: anxiolytics and treating the cause.
- Match the drug to the input: ondansetron for chemotherapy and gut causes, antihistamines or hyoscine for motion, D2 antagonists for drug and metabolic causes.
- 2.
Compare metoclopramide and ondansetron.
Show answer
- Metoclopramide: D2 antagonist (central and gut), 5-HT4 agonist and weak 5-HT3 antagonist; antiemetic and prokinetic; extrapyramidal effects, avoid in obstruction and Parkinson disease.
- Ondansetron: selective 5-HT3 antagonist at vagal afferents and CTZ; no prokinetic effect; constipation, headache, QT prolongation.
- Choice depends on cause and patient factors.
- 3.
A young woman develops neck twisting and upward eye deviation after an antiemetic. Explain and manage.
Show answer
- Acute dystonic reaction to a central D2 antagonist (metoclopramide, prochlorperazine, droperidol).
- Striatal dopamine block leaves cholinergic activity relatively unopposed.
- Treat with a centrally acting anticholinergic (benztropine) or an anticholinergic antihistamine; usually rapid response.
- Recurrence possible as the antiemetic outlasts the antidote; avoid the drug in future.
- 4.
Describe the mechanism of action of proton pump inhibitors.
Show answer
- Weak base prodrugs absorbed and delivered to parietal cells; trapped and activated in the acidic canaliculus.
- Sulfenamide forms covalent disulfide bonds with cysteines on H+/K+ ATPase: irreversible inhibition of the final common step of acid secretion.
- Duration depends on pump turnover, not plasma half-life; most effective given before meals.
- CYP2C19 metabolism; interactions with clopidogrel (omeprazole) and some others.
- 5.
Why are proton pump inhibitors used after endoscopic treatment of a bleeding ulcer?
Show answer
- Acid and pepsin dissolve clot; platelet aggregation is impaired at low pH.
- Raising intragastric pH stabilises clot and reduces rebleeding.
- They do not stop active arterial bleeding; endoscopic therapy does.
- 6.
How do terlipressin and octreotide help in variceal bleeding?
Show answer
- Terlipressin: prodrug of lysine vasopressin; V1 agonist; splanchnic vasoconstriction lowers portal inflow and pressure.
- Octreotide: somatostatin analogue; inhibits release of vasodilator gut hormones (glucagon), causing splanchnic vasoconstriction.
- Terlipressin adverse effects: myocardial, gut and peripheral ischaemia, hyponatraemia.
- Used with antibiotics and early endoscopic band ligation.
- 7.
How does lactulose treat hepatic encephalopathy?
Show answer
- Non-absorbed disaccharide fermented by colonic bacteria to short-chain acids.
- Lower colonic pH converts ammonia to ammonium, which is not absorbed.
- Osmotic laxative effect shortens transit and reduces ammonia-producing bacteria.
- Rifaximin, a poorly absorbed antibiotic, is added in recurrent encephalopathy to reduce ammonia-producing bacteria.
- 8.
Why does loperamide not cause opioid effects at normal doses, and why is misuse dangerous?
Show answer
- Mu agonist with poor oral bioavailability and P-glycoprotein efflux from the brain.
- Very large amounts, or P-glycoprotein inhibitors, allow central effects.
- At high levels it blocks cardiac sodium and hERG potassium channels: QRS widening, QT prolongation, ventricular arrhythmias.
- 9.
What is akathisia, and why does it matter in the ED?
Show answer
- Subjective restlessness and an urge to move after dopamine antagonists, often within an hour of IV dosing.
- Mistaken for agitation or anxiety; patients may leave or become distressed.
- Stop the drug; treatment options include benzodiazepines, anticholinergics or propranolol per local guidance.
Practise this week
- Primary MCQs: pharmacology
- Primary SAQs, marked part by part
- Primary vivas
- Viva Examiner: practise answering aloud
Week 18 in the other subjects
- Physiology: Synapses, neuromuscular junction and muscle
- Measurement and equipment: Neuromuscular and depth of anaesthesia monitoring
Not affiliated with the Australian and New Zealand College of Anaesthetists (ANZCA). Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.